The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternative...
Enregistré dans:
Auteurs principaux: | Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Pérez-Martínez, Manel Juan, Cristina Eguizabal |
---|---|
Format: | article |
Langue: | EN |
Publié: |
MDPI AG
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e56 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
par: Sergey Kulemzin, et autres
Publié: (2021) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
par: Erica L. Heipertz, et autres
Publié: (2021) -
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
par: Zhengli Xu, et autres
Publié: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
par: Cristina Aparicio, et autres
Publié: (2021) -
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
par: Rodion A. Velichinskii, et autres
Publié: (2021)